Semaglutide is a GLP-1 receptor agonist (glucagon-like peptide-1 analog) originally developed for the treatment of type 2 diabetes and later approved for chronic weight management under brand names such as Ozempic®, Wegovy®, and Rybelsus®. It works by mimicking the body’s natural GLP-1 hormone, which regulates blood sugar, slows gastric emptying, and reduces appetite through direct effects on the brain’s hunger centers.
Semaglutide has revolutionized the approach to obesity treatment, offering clinically significant weight loss with once-weekly dosing and a strong safety profile — now also being explored in longevity, cardiovascular protection, and neurodegenerative disease prevention.
